DNLI News and Press, Denali Therapeutics Inc. From 10/31/22

Summary Baillie Gifford’s 13F portfolio value decreased from ~$97.51B to ~$96.99B this quarter. They increased Shopify, Roblox, Zoom Video, and Twilio while reducing Albemarle Corporation and Li Auto ADR. The top three positions are Tesla Motors, Moderna, and MercadoLib...

Summary Denali Therapeutics initiated a phase 3 study, using BIIB122 for the treatment of Parkinson's Disease patients with the pathogenic mutation of LRRK2, in October of 2022. The company initiated a phase 2b study, using BIIB122 for the treatment of early-stage Parkinson's Dise...

SOUTH SAN FRANCISCO, Calif., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced the closing of its upsized underwritten public offering of 11,933,962 shares of its common stock at a price to the public of $26.50 per share, which includes the exercise i...

Denali Therapeutics ( NASDAQ: DNLI ) has priced its underwritten public offering of 10,377,359 shares of its common stock at a price to the public of $26.50/share. All of the shares are to be sold by Denali Therapeutics. Underwriters are granted a 30-day option to purc...

SOUTH SAN FRANCISCO, Calif., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced the pricing of its underwritten public offering of 10,377,359 shares of its common stock at a price to the public of $26.50 per share. All of the shares are to be sold by D...

Denali Therapeutics ( NASDAQ: DNLI ) plans to sell $250M in common stock as part of an underwritten public offering. Shares are down ~6% in post-market trading. Goldman Sachs, J.P. Morgan, and Jefferies are acting as joint book-runners. Underwriters have a ...

Biogen ( NASDAQ: BIIB ) and Denali Therapeutics ( NASDAQ: DNLI ) have commenced dosing in the phase 3 LIGHTHOUSE study examining BIIB122 for Parkinson’s disease in those with a certain genetic mutation. The primary endpoint is time to confirmed wors...

Global Phase 3 study to evaluate efficacy and safety of BIIB122, a small molecule inhibitor of LRRK2 LRRK2 mutations are one of the most common genetic drivers of Parkinson’s disease Targeting LRRK2 has the potential to impact the underlying biology and slow the progression...

Additional one-year data continue to show rapid and sustained normalization to healthy levels of CSF heparan sulfate and improvements in biomarkers of lysosomal function consistent with durable central nervous system activity Safety profile, now with up to 85 weeks of dosing, cont...

Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. Baron Growth Fund declined 18.69% (Institutional Shares) during the quarter ended June 30, 2022. We think that the co...